Vanzacaftor-d4

Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor (HY-145603) . Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR) . Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases[1][2].

Product Specifications

Product Name Alternative

VX-121-d4

UNSPSC

12352005

Target

CFTR; Chloride Channel; Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

CC1(C[C@@]([H])(C([2H])([2H])N1C2=NC(N3C=CC(OC([2H])(CC4C5(C46CC6)CC5)[2H])=N3)=CC=C27)CCC/N=C8NC(S(=O)(NC7=O)=O)=CC=C\8)C

Molecular Formula

C32H35D4N7O4S

Molecular Weight

621.79

References & Citations

[1]Uluer AZ, et al. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials[J]. Lancet Respir Med. 2023 Jun;11 (6) :550-562.|[2]Kolski-Andreaco A, et al. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator (CFTR) correctors VX-445 and VX-121[J]. J Clin Invest. 2024 Jul 2:e176328.